We tested MMRi64 mainly in leukemia/lymphoma cells because the p53 pathway is critical for apoptosis induction,46 lymphoma development10, 33, 34 and restoration of p53 in mice leads to regression of autochthonous lymphomas.4 Importantly, p53 mutation rate is relatively low (4.2% of diffuse large B-cell lymphoma, TCGA data) and about 80–90% of lymphoma patients have a wt-p53 status.47 Therefore, p53-based therapy would benefit a large group of lymphoma/leukemia patients. The gene discussed is TP53; the disease is lymphoma.